In France, the Exploitant role is a mandatory regulatory requirement for any pharmaceutical company wishing to commercialize a medicinal product. This concept is specific to the French pharmaceutical framework and goes far beyond the role of a distributor or a simple local representative. The Exploitant is the legally designated entity responsible for the commercialization, compliance, and ongoing management of a medicinal product on the French market.
Under French Public Health Law, the Exploitant oversees all post-authorization activities linked to a medicine. These responsibilities are strictly supervised by ANSM and are designed to ensure a high level of patient safety and regulatory control at national level. French authorities require that these obligations be managed by a qualified structure established in France, with clearly identified accountability.
The Exploitant is responsible for regulatory compliance, including holding an authorized pharmaceutical establishment status and maintaining a complete Exploitant dossier in French. It must ensure that all activities related to the product fully comply with French legislation throughout the product lifecycle.
Pharmacovigilance is a core obligation of the Exploitant. This includes continuous safety monitoring, local adverse event reporting, 24/7 availability of qualified safety personnel, and proactive management of safety signals in coordination with European and global systems.
The Exploitant also holds legal responsibility for medical information and promotional activities in France. All advertising and communications must comply with strict national rules governing interactions with healthcare professionals and patients.
Quality assurance is another central pillar of the Exploitant role. The Exploitant oversees batch traceability, quality documentation, recall preparedness, and coordination with manufacturers, importers, and Qualified Persons to ensure that only compliant batches reach the French market.
In addition, the Exploitant supervises storage and distribution activities, even when these are subcontracted, ensuring compliance with Good Distribution Practices and supply chain integrity.
French regulations require the appointment of a Responsible Pharmacist (Pharmacien Responsable) within the Exploitant organization. This individual bears legal accountability for all pharmaceutical operations and acts as the primary point of contact with health authorities.
For international pharmaceutical companies, establishing and maintaining an Exploitant structure can be complex, time-consuming, and resource-intensive. This is where AzurBio provides critical value.
AzurBio supports pharmaceutical companies by acting as a licensed local Exploitant or by assisting in the creation and structuring of an in-house Exploitant organization. Its teams manage regulatory compliance, pharmacovigilance, quality systems, batch oversight, and authority interactions on behalf of clients.
By leveraging an already authorized structure and a multidisciplinary team with deep expertise in French regulations, AzurBio enables faster market entry while ensuring full compliance. This allows pharmaceutical companies to focus on their products and commercial strategy, confident that all regulatory, quality, and safety obligations in France are fully controlled.
In this way, AzurBio transforms the Exploitant requirement from a regulatory constraint into a secure, efficient, and compliant pathway to successful commercialization in the French pharmaceutical market.
👉 Get in touch with AzurBio now and take the first step toward a smooth French market entry. We look forward to helping you succeed in France’s pharmaceutical market!